We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Stay Ahead of the Game With Halozyme Therapeutics (HALO) Q4 Earnings: Wall Street's Insights on Key Metrics
Read MoreHide Full Article
The upcoming report from Halozyme Therapeutics (HALO - Free Report) is expected to reveal quarterly earnings of $2.15 per share, indicating an increase of 70.6% compared to the year-ago period. Analysts forecast revenues of $448.62 million, representing an increase of 50.5% year over year.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 10.9% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
That said, let's delve into the average estimates of some Halozyme Therapeutics metrics that Wall Street analysts commonly model and monitor.
Analysts expect 'Revenues- Product sales, net' to come in at $115.69 million. The estimate indicates a change of +45.8% from the prior-year quarter.
Analysts forecast 'Revenues- Royalties' to reach $262.14 million. The estimate suggests a change of +53.8% year over year.
Analysts predict that the 'Revenues- Revenues under collaboration agreements' will reach $61.31 million. The estimate points to a change of +27.1% from the year-ago quarter.
Shares of Halozyme Therapeutics have demonstrated returns of +7.1% over the past month compared to the Zacks S&P 500 composite's -2% change. With a Zacks Rank #3 (Hold), HALO is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Stay Ahead of the Game With Halozyme Therapeutics (HALO) Q4 Earnings: Wall Street's Insights on Key Metrics
The upcoming report from Halozyme Therapeutics (HALO - Free Report) is expected to reveal quarterly earnings of $2.15 per share, indicating an increase of 70.6% compared to the year-ago period. Analysts forecast revenues of $448.62 million, representing an increase of 50.5% year over year.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 10.9% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
That said, let's delve into the average estimates of some Halozyme Therapeutics metrics that Wall Street analysts commonly model and monitor.
Analysts expect 'Revenues- Product sales, net' to come in at $115.69 million. The estimate indicates a change of +45.8% from the prior-year quarter.
Analysts forecast 'Revenues- Royalties' to reach $262.14 million. The estimate suggests a change of +53.8% year over year.
Analysts predict that the 'Revenues- Revenues under collaboration agreements' will reach $61.31 million. The estimate points to a change of +27.1% from the year-ago quarter.
View all Key Company Metrics for Halozyme Therapeutics here>>>Shares of Halozyme Therapeutics have demonstrated returns of +7.1% over the past month compared to the Zacks S&P 500 composite's -2% change. With a Zacks Rank #3 (Hold), HALO is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .